Skip to content
Aram F. Hezel, M.D.

Aram F. Hezel, M.D.

Cancer

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

About Me

Serving the University and Rochester community as Chief of the Division of Hematology and Oncology is a great privilege and honor.

Oncology is a field of work I chose driven by the loss of my grandfather from cancer as a young man, and then later in medical school, as I came to understand ...
Serving the University and Rochester community as Chief of the Division of Hematology and Oncology is a great privilege and honor.

Oncology is a field of work I chose driven by the loss of my grandfather from cancer as a young man, and then later in medical school, as I came to understand the scientific challenges cancer medicine presented and the deep satisfaction of caring for and helping people facing cancer. In particular I found the people I met in the clinics and labs who devoted themselves to this area to be role models and sources of inspiration.

Every patient is different – and so is each cancer. Understanding patients and their families, what is important to them, and providing the best possible care is my goal. While many people face cancer, each person does so with specific concerns, fears and beliefs. I will always do my best to provide the highest quality care, while preserving a patient's dignity.

My areas of special interest include clinical trials with new therapies for gastrointestinal cancers, and understanding the genetics and biology of pancreatic and liver cancers. My clinical specialty, caring for patients with gastro-intestinal cancers, both motivates and informs my research aspirations.

In the course of this work, I have promoted physician-scientist training at multiple levels including through the cancer center and the national cancer research community. Specifically, I have mentored numerous oncology fellows, postdoctoral fellows and PhD candidates, including MD-PhD students. As a physician, researcher and leader at URMC and Wilmot I am committed to enhancing the diversity of our community.

Conditions I Treat

- Esophageal cancer
- Stomach cancer
- Liver cancer
- Pancreatic cancer
- Bowel cancer
- Colon cancer
- Rectal cancer
- Anal cancer
- Gastrointestinal stromal tumors (GIST)
- Neuroendocrine tumors
- Carcinoid tumors

Professional Background

Dr. Hezel is Chief of its Division of Hematology and Oncology and Associate Professor in the Department of Medicine, John and Ethel Heselden Professor and has joint appointments as associate professor of biomedical genetics and as associate professor of oncology at the Wilmot Cancer Institute.
<...
Dr. Hezel is Chief of its Division of Hematology and Oncology and Associate Professor in the Department of Medicine, John and Ethel Heselden Professor and has joint appointments as associate professor of biomedical genetics and as associate professor of oncology at the Wilmot Cancer Institute.

Dr. Hezel's research focuses on cancer genetics, animal modelling, and therapeutic development in pancreatic and hepato-biliary tumors and clinical trials in gastro-intestinal malignancies. In biliary tract cancers he has studied how mutations in key oncogenes and tumor suppressors cause cancer to arise and to understand the cells of origin in the liver as well as how liver injury can impact disease. Hezel's clinical focus is on treating patients diagnosed with gastrointestinal cancers including those of the pancreas and liver and on clinical research testing new therapies in gastrointestinal malignancies. His research has appeared in Cancer Research, Cell Reports, Nature, and the British Journal of Cancer among other publications.

Hezel is an active member of the American Society of Clinical Oncology, as well as the American Association for Cancer Research, and his work is supported by the National Cancer Institute.

Hezel, a graduate of Vassar College, received his MD from the State University of New York at Buffalo in 2000. He completed his residency in internal medicine at Beth Israel Deaconess Medical Center of Boston followed by fellowship at the Dana-Farber/Harvard Partners Oncology/Hematology Program and a postdoctoral research fellowship at the Dana Farber Cancer Institute. Hezel came to Rochester in 2009 from the Massachusetts General Hospital Cancer Center and Harvard Medical School.

Certified Specialties

Medical Oncology - American Board of Internal Medicine

Faculty Appointments

Professor - Department of Medicine, Hematology/Oncology (SMD)

John and Ethel Heselden Professorship - Department of Medicine, Hematology/Oncology (SMD)

Chief - Department of Medicine, Hematology/Oncology (SMD)

Professor - Department of Biomedical Genetics (SMD) - Joint

Professor - Cancer Center - Joint

Connect with Aram F. Hezel, M.D.

Credentials

Residency & Fellowship

Fellowship, Medical Oncology, Dana-Farber Cancer Institute. 2003 - 2006

Residency, Internal Medicine, Beth Israel Deaconess Medical Center-Main Campus. 2001 - 2003

Internship, Beth Israel Deaconess Medical Center-Main Campus. 2000 - 2001

Education

MD | SUNY at Buffalo-School of Medicine & Biomedical Sciences (USA). 2000

Awards

Patient & Family Centered Care Top Performer Award. 2013

American Cancer Society Career Development Award. 2013

Teacher of the Year Award. 2012

Teacher of the Year Award. 2011

Edelman Gardner Research Award. 2010

Howard Hughes Medical Institute Physician-Scientist Early Career Award. 2007

NCI Career Development Award: K08 CA122835-03. 2006

PanCAN/ASCO Young Investigator Award. 2005

Loretta A. Jordan Award for Research of Neoplastic Disease. 2000

Robin Bannerman Memorial Research Award. 2000

Howard Hughes Medical Institute Research Training Fellowship for Medical Students. 1999

Howard Hughes Medical Institute Research Training Fellowship. 1998

John Harford/American Federation for Aging Research. 1997

Dean's List for Academic Excellence. 1996 - 1997

Publications

Journal Articles

SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma: Clinicopathologic and immunohistochemical study.

Chen IY, Ettel MG, Bell PD, Huber AR, Findeis-Hosey JJ, Wang W, Hezel AF, Dunne RF, Drage MG, Agostini-Vulaj D

Human pathology.. 2024 January 31 Epub 01/31/2024.

Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial.

Thompson HM, Omer DM, Lin S, Kim JK, Yuval JB, Veheij FS, Qin LX, Gollub MJ, Wu AJ, Lee M, Patil S, Hezel AF, Marcet JE, Cataldo PA, Polite BN, Herzig DO, Liska D, Oommen S, Friel CM, Ternent CA, Coveler AL, Hunt SR, Garcia-Aguilar J,

JAMA network open.. 2024 January 27 (1):e2350903. Epub 01/02/2024.

Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling.

Dudgeon C, Casabianca A, Harris C, Ogier C, Bellina M, Fiore S, Bernet A, Ducarouoge B, Goldschneider D, Su X, Pitarresi J, Hezel A, De S, Narrow W, Soliman F, Shields C, Vendramini-Costa DB, Prela O, Wang L, Astsaturov I, Mehlen P, Carpizo DR

Cell reports.. 2023 November 242 (11):113369. Epub 11/02/2023.

Glutathione supports lipid abundance .

Asantewaa G, Tuttle ET, Ward NP, Kang YP, Kim Y, Kavanagh ME, Girnius N, Chen Y, Duncan R, Rodriguez K, Hecht F, Zocchi M, Smorodintsev-Schiller L, Scales TQ, Taylor K, Alimohammadi F, Sechrist ZR, Agostini-Vulaj D, Schafer XL, Chang H, Smith Z, O'Connor TN, Whelan S, Selfors LM, Crowdis J, Gray GK, Bronson RT, Brenner D, Rufini A, Dirksen RT, Hezel AF, Huber AR, Munger J, Cravatt BF, Vasiliou V, Cole CL, DeNicola GM, Harris IS

bioRxiv : the preprint server for biology.. 2023 February 11 Epub 02/11/2023.

Spatially-resolved single-cell assessment of pancreatic cancer expression subtypes reveals co-expressor phenotypes and extensive intra-tumoral heterogeneity.

Williams HL, Dias Costa A, Zhang J, Raghavan S, Winter PS, Kapner KS, Ginebaugh SP, Väyrynen SA, Väyrynen JP, Yuan C, Navia AW, Wang J, Yang A, Bosse TL, Kalekar RL, Lowder KE, Lau MC, Elganainy D, Morales-Oyarvide V, Rubinson DA, Singh H, Perez K, Cleary JM, Clancy TE, Wang J, Mancias JD, Brais LK, Hill ER, Kozak MM, Linehan DC, Dunne RF, Chang DT, Koong AC, Hezel AF, Hahn WC, Shalek AK, Aguirre AJ, Nowak JA, Wolpin BM

Cancer research.. 2022 December 2 Epub 12/02/2022.

Neoadjuvant chemotherapy is associated with altered immune cell infiltration and an anti-tumorigenic microenvironment in resected pancreatic cancer.

Dias Costa A, Väyrynen SA, Chawla A, Zhang J, Väyrynen JP, Lau MC, Williams HL, Yuan C, Morales-Oyarvide V, Elganainy D, Singh H, Cleary JM, Perez K, Ng K, Freed-Pastor W, Mancias JD, Dougan SK, Wang J, Rubinson DA, Dunne RF, Kozak MM, Brais L, Reilly E, Clancy T, Linehan DC, Chang DT, Hezel AF, Koong AC, Aguirre A, Wolpin BM, Nowak JA

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2022 September 21 Epub 09/21/2022.

Arid1a mutation suppresses TGF-? signaling and induces cholangiocarcinoma.

Guo B, Friedland SC, Alexander W, Myers JA, Wang W, O'Dell MR, Getman M, Whitney-Miller CL, Agostini-Vulaj D, Huber AR, Mello SS, Vertino PM, Land HK, Steiner LA, Hezel AF

Cell reports.. 2022 August 3040 (9):111253. Epub 1900 01 01.

GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity.

Ruffolo LI, Jackson KM, Kuhlers PC, Dale BS, Figueroa Guilliani NM, Ullman NA, Burchard PR, Qin SS, Juviler PG, Keilson JM, Morrison AB, Georger M, Jewell R, Calvi LM, Nywening TM, O'Dell MR, Hezel AF, De Las Casas L, Lesinski GB, Yeh JJ, Hernandez-Alejandro R, Belt BA, Linehan DC

Gut.. 2021 August 19 Epub 08/19/2021.

Prevalence of and factors associated with treatment modification at first cycle in older adults with advanced cancer receiving palliative treatment.

Mohamed MR, Kyi K, Mohile SG, Xu H, Culakova E, Loh KP, Flannery M, Obrecht S, Ramsdale E, Patil A, Dunne RF, DiGiovanni G, Hezel A, Burnette B, Desai N, Giguere J, Magnuson A

Journal of geriatric oncology.. 2021 July 13 Epub 07/13/2021.

FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.

Vallejo A, Erice O, Entrialgo-Cadierno R, Feliu I, Guruceaga E, Perugorria MJ, Olaizola P, Muggli A, Macaya I, O'Dell M, Cordoba BR, Ortiz-Espinosa S, Hezel AF, Arozarena I, Lecanda F, Avila MA, Fernández-Barrena MG, Evert M, Ponz-Sarvise M, Calvisi DF, Banales JM, Vicent S

Journal of hepatology.. 2021 April 14 Epub 04/14/2021.

Composition, spatial characteristics, and prognostic significance of myeloid cell infiltration in pancreatic cancer.

Väyrynen SA, Zhang J, Yuan C, Väyrynen JP, Dias Costa A, Williams H, Morales-Oyarvide V, Lau MC, Rubinson DA, Dunne RF, Kozak MM, Wang W, Agostini-Vulaj D, Drage MG, Brais LK, Reilly E, Rahma OE, Clancy TE, Wang J, Linehan DC, Aguirre A, Fuchs CS, Coussens LM, Chang DT, Koong AC, Hezel AF, Ogino S, Nowak JA, Wolpin BM

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2020 December 1 Epub 12/01/2020.

Insulin-like growth factor-1 receptor expression and disease recurrence and survival in patients with resected pancreatic ductal adenocarcinoma.

Du C, da Silva A, Morales-Oyarvide V, Dias Costa A, Kozak MM, Dunne RF, Rubinson DA, Perez K, Masugi Y, Hamada T, Brais LK, Yuan C, Babic A, Ducar MD, Thorner AR, Aguirre A, Kulke MH, Ng K, Clancy TE, Findeis-Hosey JJ, Chang DT, Hornick JL, Fuchs CS, Ogino S, Koong AC, Hezel AF, Wolpin BM, Nowak JA

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.. 2020 May 28 Epub 05/28/2020.

Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma.

Chung KM, Singh J, Lawres L, Dorans KJ, Garcia C, Burkhardt DB, Robbins R, Bhutkar A, Cardone R, Zhao X, Babic A, Vayrynen SA, Dias Costa A, Nowak JA, Chang DT, Dunne RF, Hezel AF, Koong AC, Wilhelm JJ, Bellin MD, Nylander V, Gloyn AL, McCarthy MI, Kibbey RG, Krishnaswamy S, Wolpin BM, Jacks T, Fuchs CS, Muzumdar MD

Cell.. 2020 April 16 Epub 04/16/2020.

Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution Experience.

Li F, Nielsen G, Baran A, Hu J, Wallace D, Preslar M, Fleming F, Temple L, Dunne RF, Noel M, Hezel AF, Tejani MA

Clinical colorectal cancer.. 2020 April 14 Epub 04/14/2020.

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

O'Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W, Fisher G, Hezel A, Chang SC, Vlahovic G, Takahashi O, Yang Y, Fitts D, Philip PA

JAMA oncology.. 2019 July 18 Epub 07/18/2019.

Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.

Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Qian ZR, Welch MW, Brais LK, Da Silva A, Bui JL, Yuan C, Li T, Li W, Masuda A, Gu M, Bullock AJ, Chang DT, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar MD, Wollison BM, Khalaf N, Perez K, Syngal S, Aguirre AJ, Hahn WC, Meyerson ML, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Nowak JA, Wolpin BM

Genetics in medicine : official journal of the American College of Medical Genetics.. 2019 January 21 (1):213-223. Epub 07/02/2018.

ARID1A, a SWI/SNF subunit, is critical to acinar cell homeostasis and regeneration and is a barrier to transformation and epithelial-mesenchymal transition in the pancreas.

Wang W, Friedland SC, Guo B, O'Dell MR, Alexander WB, Whitney-Miller CL, Agostini-Vulaj D, Huber AR, Myers JR, Ashton JM, Dunne RF, Steiner LA, Hezel AF

Gut.. 2018 September 18 Epub 09/18/2018.

and Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma.

Hill MA, Alexander WB, Guo B, Kato Y, Patra KC, O'Dell MR, McCall MN, Whitney-Miller CL, Bardeesy N, Hezel AF

Cancer research.. 2018 August 1578 (16):4445-4451. Epub 06/05/2018.

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

Fabrizio DA, George TJ, Dunne RF, Frampton G, Sun J, Gowen K, Kennedy M, Greenbowe J, Schrock AB, Hezel AF, Ross JS, Stephens PJ, Ali SM, Miller VA, Fakih M, Klempner SJ

Journal of gastrointestinal oncology.. 2018 August 9 (4):610-617. Epub 1900 01 01.

Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.

Qian ZR, Rubinson DA, Nowak JA, Morales-Oyarvide V, Dunne RF, Kozak MM, Welch MW, Brais LK, Da Silva A, Li T, Li W, Masuda A, Yang J, Shi Y, Gu M, Masugi Y, Bui J, Zellers CL, Yuan C, Babic A, Khalaf N, Aguirre A, Ng K, Miksad RA, Bullock AJ, Chang DT, Tseng JF, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar M, Wollison B, Laing A, Hahn WC, Meyerson M, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Wolpin BM

JAMA oncology.. 2018 March 84 (3):e173420. Epub 03/08/2018.

Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713.

Leichman CG, McDonough SL, Smalley SR, Billingsley KG, Lenz HJ, Beldner MA, Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS

Clinical colorectal cancer.. 2018 March 17 (1):e121-e125. Epub 10/24/2017.

Serum Response Factor Is Essential for Maintenance of Podocyte Structure and Function.

Guo B, Lyu Q, Slivano OJ, Dirkx R, Christie CK, Czyzyk J, Hezel AF, Gharavi AG, Small EM, Miano JM

Journal of the American Society of Nephrology : JASN.. 2018 February 29 (2):416-422. Epub 11/07/2017.

Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival.

Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Bui JL, Yuan C, Qian ZR, Babic A, Da Silva A, Nowak JA, Khalaf N, Brais LK, Welch MW, Zellers CL, Ng K, Chang DT, Miksad RA, Bullock AJ, Tseng JF, Swanson RS, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Hornick JL, Ogino S, Fuchs CS, Hezel AF, Koong AC, Wolpin BM

British journal of cancer.. 2017 December 5117 (12):1874-1882. Epub 10/05/2017.

Research priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia.

Dunne RF, Mustian KM, Garcia JM, Dale W, Hayward R, Roussel B, Buschmann MM, Caan BJ, Cole CL, Fleming FJ, Chakkalakal JV, Linehan DC, Hezel AF, Mohile SG

Current opinion in supportive and palliative care.. 2017 December 11 (4):278-286. Epub 1900 01 01.

Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.

Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, Jenkins RL, Rieger-Christ KM, Sullivan TB, Hezel AF, Liss AS, Mizukami Y, Goyal L, Ferrone CR, Zhu AX, Joung JK, Shokat KM, Benes CH, Bardeesy N

Cancer discovery.. 2016 July 6 (7):727-39. Epub 05/26/2016.

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.

Adjei AA, Richards DA, El-Khoueiry A, Braiteh F, Becerra CH, Stephenson JJ, Hezel AF, Sherman M, Garbo L, Leffingwell DP, Iverson C, Miner JN, Shen Z, Yeh LT, Gunawan S, Wilson DM, Manhard KJ, Rajagopalan P, Krissel H, Clendeninn NJ

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2016 May 1522 (10):2368-76. Epub 12/07/2015.

Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma.

Deshpande V, Konstantinidis IT, Castillo CF, Hezel AF, Haigis KM, Ting DT, Bardeesy N, Goyal L, Zhu AX, Warshaw AL, Lillemoe KD, Ferrone CR

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.. 2016 May 20 (5):953-9. Epub 03/08/2016.

Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma.

Mohamed M, Katz AW, Tejani MA, Sharma AK, Kashyap R, Noel MS, Qiu H, Hezel AF, Ramaraju GA, Dokus MK, Orloff MS

Advances in radiation oncology.. 2016 1 (1):35-42. Epub 12/29/2015.

Corrigendum: Mutant IDH inhibits HNF-4? to block hepatocyte differentiation and promote biliary cancer.

Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N

Nature.. 2015 December 3528 (7580):152. Epub 11/18/2015.

Genetics and Biology of Pancreatic Ductal Adenocarcinoma.

Dunne RF, Hezel AF

Hematology/oncology clinics of North America.. 2015 August 29 (4):595-608. Epub 06/10/2015.

Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).

Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, Lim HJ, Hezel AF, Vaccaro GM, Blanke CD

Cancer.. 2015 July 1121 (13):2193-7. Epub 03/30/2015.

Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.

Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R, Benes CH, Engelman J, Bardeesy N

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2015 January 1521 (2):396-404. Epub 10/27/2014.

Mutant IDH inhibits HNF-4? to block hepatocyte differentiation and promote biliary cancer.

Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N

Nature.. 2014 September 4513 (7516):110-4. Epub 07/02/2014.

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.

Hezel AF, Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, Goyal L, Clark JW, Blaszkowsky LS, Murphy JE, Zheng H, Khorana AA, Connolly GC, Hyrien O, Baran A, Herr M, Ng K, Sheehan S, Harris DJ, Regan E, Borger DR, Iafrate AJ, Fuchs C, Ryan DP, Zhu AX

British journal of cancer.. 2014 July 29111 (3):430-6. Epub 06/24/2014.

Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression.

Kinsey C, Balakrishnan V, O'Dell MR, Huang JL, Newman L, Whitney-Miller CL, Hezel AF, Land H

Cell reports.. 2014 May 227 (4):1143-55. Epub 05/01/2014.

Phase 1 study of N(1),N(11)?diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.

Goyal L, Supko JG, Berlin J, Blaszkowsky LS, Carpenter A, Heuman DM, Hilderbrand SL, Stuart KE, Cotler S, Senzer NN, Chan E, Berg CL, Clark JW, Hezel AF, Ryan DP, Zhu AX

Cancer chemotherapy and pharmacology.. 2013 December 72 (6):1305-14. Epub 1900 01 01.

New and emerging treatment options for biliary tract cancer.

Noel MS, Hezel AF

OncoTargets and therapy.. 2013 October 306 :1545-52. Epub 10/30/2013.

Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer.

McCleary NJ, Odejide O, Szymonifka J, Ryan D, Hezel A, Meyerhardt JA

Clinical colorectal cancer.. 2013 March 12 (1):62-9. Epub 10/24/2012.

Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.

Mondo EL, Noel MS, Katz AW, Schoeniger LO, Hezel AF

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2013 January 2031 (3):e37-9. Epub 12/10/2012.

Diabetes mellitus impacts risk of macrovascular invasion in patients undergoing transplantation for hepatocellular carcinoma.

Connolly GC, Safadjou S, Kashyap R, Chen R, Orloff MS, Hezel AF

BMC gastroenterology.. 2013 January 1413 :9. Epub 01/14/2013.

Diabetes mellitus is associated with the presence of metastatic spread at disease presentation in hepatocellular carcinoma.

Connolly GC, Safadjou S, Chen R, Nduaguba A, Dunne R, Khorana AA, Hezel AF

Cancer investigation.. 2012 December 30 (10):698-702. Epub 10/16/2012.

TGF-? and ?v?6 integrin act in a common pathway to suppress pancreatic cancer progression.

Hezel AF, Deshpande V, Zimmerman SM, Contino G, Alagesan B, O'Dell MR, Rivera LB, Harper J, Lonning S, Brekken RA, Bardeesy N

Cancer research.. 2012 September 1572 (18):4840-5. Epub 07/11/2012.

A phase 2 study of oral MKC-1, an inhibitor of importin-?, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer.

Faris JE, Arnott J, Zheng H, Ryan DP, Abrams TA, Blaszkowsky LS, Clark JW, Enzinger PC, Hezel AF, Ng K, Wolpin BM, Kwak EL

Investigational new drugs.. 2012 August 30 (4):1614-20. Epub 07/29/2011.

Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation.

Katz AW, Chawla S, Qu Z, Kashyap R, Milano MT, Hezel AF

International journal of radiation oncology, biology, physics.. 2012 July 183 (3):895-900. Epub 12/13/2011.

Autophagy in intra-hepatic cholangiocarcinoma.

Huang JL, Hezel AF

Autophagy.. 2012 July 18 (7):1148-9. Epub 07/01/2012.

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.

Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC, DePinho RA

Cell.. 2012 April 27149 (3):656-70. Epub 1900 01 01.

Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.

O'Dell MR, Huang JL, Whitney-Miller CL, Deshpande V, Rothberg P, Grose V, Rossi RM, Zhu AX, Land H, Bardeesy N, Hezel AF

Cancer research.. 2012 March 1572 (6):1557-67. Epub 01/20/2012.

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ

The oncologist.. 2012 17 (1):72-9. Epub 12/16/2011.

Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.

Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW

The oncologist.. 2012 17 (1):14. Epub 12/30/2011.

PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-?B-cytokine network.

Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H, Fletcher-Sananikone E, Zhang H, Liu Y, Wang W, Ren X, Zheng H, Kimmelman AC, Paik JH, Lim C, Perry SR, Jiang S, Malinn B, Protopopov A, Colla S, Xiao Y, Hezel AF, Bardeesy N, Turley SJ, Wang YA, Chin L, Thayer SP, DePinho RA

Cancer discovery.. 2011 July 1 (2):158-69. Epub 05/23/2011.

Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy.

Alexander BM, Fernandez-Del Castillo C, Ryan DP, Kachnic LA, Hezel AF, Niemierko A, Willett CG, Kozak KR, Blaszkowsky LS, Clark JW, Warshaw AL, Hong TS

Gastrointestinal cancer research : GCR.. 2011 July 4 (4):116-21. Epub 1900 01 01.

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX, Hezel AF

BMC cancer.. 2011 February 811 :60. Epub 02/08/2011.

Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.

Zhu AX, Hezel AF

Hepatology : official journal of the American Association for the Study of Liver Diseases.. 2011 February 53 (2):695-704. Epub 1900 01 01.

Genetics of biliary tract cancers and emerging targeted therapies.

Hezel AF, Deshpande V, Zhu AX

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2010 July 2028 (21):3531-40. Epub 06/14/2010.

Current management of gallbladder carcinoma.

Zhu AX, Hong TS, Hezel AF, Kooby DA

The oncologist.. 2010 15 (2):168-81. Epub 02/10/2010.

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2009 June 2027 (18):3027-35. Epub 05/26/2009.

Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma.

Plentz R, Park JS, Rhim AD, Abravanel D, Hezel AF, Sharma SV, Gurumurthy S, Deshpande V, Kenific C, Settleman J, Majumder PK, Stanger BZ, Bardeesy N

Gastroenterology.. 2009 May 136 (5):1741-9.e6. Epub 01/14/2009.

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.

Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, Fuchs CS

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2009 January 1027 (2):193-8. Epub 12/01/2008.

Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer.

Kimmelman AC, Hezel AF, Aguirre AJ, Zheng H, Paik JH, Ying H, Chu GC, Zhang JX, Sahin E, Yeo G, Ponugoti A, Nabioullin R, Deroo S, Yang S, Wang X, McGrath JP, Protopopova M, Ivanova E, Zhang J, Feng B, Tsao MS, Redston M, Protopopov A, Xiao Y, Futreal PA, Hahn WC, Klimstra DS, Chin L, DePinho RA

Proceedings of the National Academy of Sciences of the United States of America.. 2008 December 9105 (49):19372-7. Epub 12/02/2008.

LKB1; linking cell structure and tumor suppression.

Hezel AF, Bardeesy N

Oncogene.. 2008 November 2427 (55):6908-19. Epub 1900 01 01.

Prognostic markers in pancreatic ductal adenocarcinomas.

Hezel AF, Bardeesy N

Cancer biology & therapy.. 2008 September 7 (9):1360-1. Epub 09/06/2008.

Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms.

Hezel AF, Gurumurthy S, Granot Z, Swisa A, Chu GC, Bailey G, Dor Y, Bardeesy N, Depinho RA

Molecular and cellular biology.. 2008 April 28 (7):2414-25. Epub 01/28/2008.

Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer.

Perera SA, Maser RS, Xia H, McNamara K, Protopopov A, Chen L, Hezel AF, Kim CF, Bronson RT, Castrillon DH, Chin L, Bardeesy N, Depinho RA, Wong KK

Carcinogenesis.. 2008 April 29 (4):747-53. Epub 02/17/2008.

Systemic therapy for biliary tract cancers.

Hezel AF, Zhu AX

The oncologist.. 2008 April 13 (4):415-23. Epub 1900 01 01.

LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis.

Gurumurthy S, Hezel AF, Sahin E, Berger JH, Bosenberg MW, Bardeesy N

Cancer research.. 2008 January 168 (1):55-63. Epub 1900 01 01.

Emerging therapies for colorectal cancer.

Hezel AF, Ryan DP

Expert opinion on investigational drugs.. 2007 June 16 (6):867-76. Epub 1900 01 01.

Influence of prednisolone on urinary calcium oxalate and struvite relative supersaturation in healthy young adult female domestic shorthaired cats.

Geyer N, Bartges JW, Kirk CA, Cox S, Hezel A, Moyers T, Hayes J

Veterinary therapeutics : research in applied veterinary

Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.

Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D, DePinho RA

Genes & development.. 2006 November 1520 (22):3130-46. Epub 1900 01 01.

Genetics and biology of pancreatic ductal adenocarcinoma.

Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA

Genes & development.. 2006 May 1520 (10):1218-49. Epub 1900 01 01.

Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.

Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, Feng B, Brennan C, Weissleder R, Mahmood U, Hanahan D, Redston MS, Chin L, Depinho RA

Proceedings of the National Academy of Sciences of the United States of America.. 2006 April 11103 (15):5947-52. Epub 04/03/2006.

K-ras activation generates an inflammatory response in lung tumors.

Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R, Tonon G, McNamara K, Marconcini LA, Hezel A, El-Bardeesy N, Bronson RT, Sugarbaker D, Maser RS, Shapiro SD, Wong KK

Oncogene.. 2006 March 3025 (14):2105-12. Epub 1900 01 01.

Telomere induced senescence: end game signaling.

Hezel AF, Bardeesy N, Maser RS

Current molecular medicine.. 2005 March 5 (2):145-52. Epub 1900 01 01.

Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation.

Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, Sharpless NE, Loda M, Carrasco DR, DePinho RA

Nature.. 2002 September 12419 (6903):162-7. Epub 1900 01 01.

Dual inactivation of RB and p53 pathways in RAS-induced melanomas.

Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L

Molecular and cellular biology.. 2001 March 21 (6):2144-53. Epub 1900 01 01.

Accelerated accumulation of somatic mutations in mice deficient in the nucleotide excision repair gene XPA.

Giese H, Dollé ME, Hezel A, van Steeg H, Vijg J

Oncogene.. 1999 February 418 (5):1257-60. Epub 1900 01 01.

Books

Journal of cellular biochemistry (2007)

Chapter: "Stromal biology of pancreatic cancer."

Authors: Chu GC; Kimmelman AC; Hezel AF; DePinho RA

Publisher: Journal of Cellular Biochemistry 2007

Ratings & Reviews

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.